Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2006

01-09-2006 | Research Letter

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione

Authors: M. Emoto, N. Fukuda, Y. Nakamori, A. Taguchi, S. Okuya, Y. Oka, Y. Tanizawa

Published in: Diabetologia | Issue 9/2006

Login to get access

Excerpt

To the Editor Thiazolidinediones are widely used in patients with type 2 diabetes. In addition to lowering plasma glucose, this class of drugs may reduce the risk of cardiovascular diseases in patients with diabetes. Despite the beneficial effect of thiazolidinediones, their use is sometimes associated with peripheral oedema. This is the most frequent adverse effect leading to discontinued treatment with thiazolidinediones in Japan. However, the mechanism by which thiazolidinediones induce oedema remains to be established. …
Literature
1.
Guan Y, Hao C, Cha DR et al (2005) Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861–866PubMedCrossRef
2.
Williams GH, Dluhy RG (2005) Disorders of the adrenal cortex. In: Kasper DL et al. (eds) Harrison’s principles of internal medicine, 16th edn. McGraw-Hill, New York, pp 2138–2140
3.
Bartter FC, Schwartz WB (1967) The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42:790–806PubMedCrossRef
4.
Emoto M, Anno T, Sato Y et al (2001) Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 50:1166–1170PubMedCrossRef
5.
Kelly IE, Han TS, Walsh K, Lean ME (1999) Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288–293PubMedCrossRef
6.
Hollenberg NK (2003) Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115(Suppl 8A):111S–115SPubMedCrossRef
7.
Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497–504PubMedCrossRef
8.
Baba T, Shimada K, Neugebauer S et al (2001) The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 24:953–954PubMedCrossRef
9.
Tooke JE, Elston LM, Gooding KM et al (2006) The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. Diabetologia 49:1064–1070PubMedCrossRef
Metadata
Title
Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione
Authors
M. Emoto
N. Fukuda
Y. Nakamori
A. Taguchi
S. Okuya
Y. Oka
Y. Tanizawa
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0313-5

Other articles of this Issue 9/2006

Diabetologia 9/2006 Go to the issue

Letter

Comment on: Gale EAM (2005) Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 48:2195–2199

Article

Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3

Research Letter

Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes

Erratum

Common variants in MODY genes increase the risk of gestational diabetes mellitus

Article

Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus

Article

Leptin and incident type 2 diabetes: risk or protection?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits